1 February 2021 in Journal of Cell Science
Fission yeast cells divide at a similar cell length with little variation about the mean. This is thought to be the result of a control mechanism that senses size and corrects for any deviations by advancing or delaying onset of mitosis. Gene deletions that advance cells into mitosis at a smaller size or delay cells entering mitosis have led to the identification of genes potentially involved in this mechanism. However, the molecular basis of this control is still not understood. In this work, we have screened for genes that when deleted increase the variability in size of dividing cells. The strongest candidate identified in this screen was mga2. The mga2 deletion strain shows a greater variation in cell length at division, with a coefficient of variation (CV) of 15–24%, while the wild-type strain has a CV of 5–8%. Furthermore, unlike wild-type cells, the mga2 deletion cells are unable to correct cell size deviations within one cell cycle. We show that the mga2 gene genetically interacts with nem1 and influences the nuclear membrane and the nuclear–cytoplasmic transport of CDK regulators.
20 February 2023 in Prenatal Diagnosis
Objectives: To develop a flexible droplet digital PCR (ddPCR) workflow to perform non‐invasive prenatal diagnosis via relative mutation dosage (RMD) for maternal pathogenic variants with a range of inheritance patterns, and to compare the accuracy of multiple analytical approaches.Methods: Cell free DNA (cfDNA) was tested from 124 archived maternal plasma samples: 88 cases for sickle cell disease and 36 for rare Mendelian conditions. Three analytical methods were compared: sequential probability ratio testing (SPRT), Bayesian and z‐score analyses.Results: The SPRT, Bayesian and z‐score analyses performed similarly well with correct prediction rates of 96%, 97% and 98%, respectively. However, there were high rates of inconclusive results for each cohort, particularly for z‐score analysis which was 31% overall. Two samples were incorrectly classified by all three analytical methods; a false negative result predicted for a fetus affected with sickle cell disease and a false positive result predicting the presence of an X‐linked IDS variant in an unaffected fetus.Conclusions: ddPCR can be applied to RMD for diverse conditions and inheritance patterns, but all methods carry a small risk of erroneous results. Further evaluation is required both to reduce the rate of inconclusive results and explore discordant results in more detail.
2 March 2026 in Prenatal Diagnosis
The clinical utility of sequencing in prenatal diagnosis is known, but diagnostic yield varies widely depending on clinical indication. Here we update an earlier systematic review reporting the diagnostic yield of prenatal sequencing in structurally abnormal fetuses, with particular focus on factors affecting diagnostic yield. The search strategy outlined in the previous review (2018–2022) was repeated to include reports published between October 2021 and January 2025. Combining these records with those from the earlier review, an overall incremental diagnostic yield of sequencing compared to chromosomal microarray analysis (CMA) was calculated and pooled in a meta‐analysis. Subgroup analyses were performed on selected, unselected, and exploratory cohorts, as well as individual phenotypic subgroups. 155 records were reviewed (89 from the current and 66 from the earlier publication). The overall pooled diagnostic yield of sequencing above CMA across all indications was 27% (95% CI 24%–30%, p < 0.0001). Subgroup analysis showed that the diagnostic yield was 40%, 20%, and 17% in selected, unselected, and exploratory subgroups, respectively. Concurrent CNV analysis of sequencing data provided nine additional diagnoses over sequential sequencing after a non‐diagnostic CMA. Prenatal sequencing provides an additional yield of 27% following a non‐diagnostic CMA across a range of fetal structural anomalies, and this increases to 40% with careful case‐selection. Sequencing continues to be a powerful diagnostic tool when performed for well‐evidenced indications.
25 November 2024 in Prenatal Diagnosis
Objective: Accurate recurrence risks are essential for genomic counselling and parental reproductive choices. Historically, Sanger sequencing was used to test parental samples, which has a limited sensitivity of ∼ 10% for detecting somatic mosaicism. Next generation sequencing (NGS) methods, utilised for non‐invasive prenatal diagnosis (NIPD) and trio prenatal exome sequencing in our laboratory, have greater sensitivity. Here we review the cases of parental somatic mosaicism we have detected and discuss its impact on management. Method: Laboratory databases from 1 January 2015 to 30 September 2022 were reviewed to identify all cases where parental somatic mosaicism was detected during NIPD and prenatal exome testing. Results: During the development of NIPD testing, we identified 10/131 (7.6%) families with parental somatic mosaicism. In six cases where NGS detected levels between 0.37% and 8.82%, prior testing with Sanger sequencing had not detected mosaicism. In our exome sequencing cohort, we detected parental mosaicism in 4/101 (3.96%) cases. Clinical features of the condition were identified in 2/14 parents. Conclusion: The sensitivity of the testing technique needs to be considered when counselling parents on recurrence risk. Parents need to be aware that modern approaches to prenatal diagnosis may allow identification of mosaicism, which may have implications for their own health and change recurrence risks for future pregnancies.
30 January 2026 in Prenatal Diagnosis
Genomic sequencing has become a key tool in the investigation of foetal anomalies, with a growing shift from targeted panels to exome and genome sequencing. These broader approaches generate significantly more data, underscoring the need for robust bioinformatics pipelines. However, practices vary widely between laboratories. This systematic review explores current differences in bioinformatics workflows, the transparency of reporting, and the clinical impact of these variations. Using a search strategy from a previous review of prenatal sequencing studies (2018–2022), we identified 89 new records. Combined with 65 from the earlier review, a total of 154 articles were included. Data extraction focused on bioinformatics pipeline details across all analytical stages, with attention to clinical relevance. We found that reporting of bioinformatics methods was frequently incomplete. Tool names and versions were often omitted, quality control steps were poorly described, and filtering strategies lacked reproducibility. These deficiencies in reporting hinder readers from fully interpreting the sequencing results and understanding the potential limitations. To address this, we propose a checklist of essential bioinformatics metrics to improve reporting standards and support reproducible, clinically meaningful analyses.